Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. O'Connor D, Valle-Inclan JE, Conde L, Bloye G, et al. Blood 2024;143:933-937.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

O'Connor D, Valle-Inclan JE, Conde L, Bloye G, et al. Noncoding mutations drive persistence of a founder preleukemic clone which initiates late relapse in T-ALL. Blood 2024;143:933-937.
PMID: 38194681